From Research at med.fsu.edu Fri Jun 5 10:12:51 2020 From: Research at med.fsu.edu (Med Research) Date: Fri, 5 Jun 2020 14:12:51 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A16CAF07@FSUCOM128.med.ad.fsu.edu> Children's Leukemia Research Association, Inc.: Research Grants The association welcomes applications for its Research Grant Program. Through the program, grants will be awarded to PhDs or MDs conducting promising research into leukemia in the hopes of isolating its causes and finding a cure. Due June 30, 2020. Med-RA deadline to receive draft documents: June 17. Damon Runyon Cancer Research Foundation Rachleff Innovation Award The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with ?high-risk/high-reward? ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. Stage 1: $200,000 for 2-year projects, no IDC. Stage 1 application due July 1, 2020. Med-RA deadline to receive draft documents: June 18. American Psychological Foundation: Grants for Early Career Psychologists Studying Links Between Mental and Physical Health The Marian R. Stuart Grant will further the research, practice, or education of an early career psychologist on the connection between mental and physical health, particularly for work that contributes to public health. Examples include but are not limited to research-based programs that teach medical doctors counseling skills; research-based programs on the effect of behavior on health; and research-based programs on psychologists? role in medical settings for the benefit of patients. Preference will be given to psychologists working in medical schools. $20,000 for one-year projects; no IDC. Due July 1, 2020. Med-RA deadline to receive draft documents: June 18. Advancing Genomic Medicine Research (R21 / R01 Clinical Trial Optional) R21 R01 These Funding Opportunity Announcements encourage applications that stimulate innovation and advance understanding of when, where, and how best to implement the use of genomic information and technologies in clinical care. Proposed projects should be broadly applicable to genomic medicine as a field, and yield findings of significance beyond a single disease, gene, or setting. Projects are strongly encouraged to include ancestrally diverse and underrepresented participants and populations. Due August 3, 2020; March 8, 2021; November 2, 2021; August 1, 2022; and March 13, 2023. Med-RA deadline to receive draft documents for August 3, 2020 due date: July 21. Congressionally Directed Medical Research Programs Duchenne Muscular Dystrophy Research Program Idea Development Award Pre-application: August 12, 2020. Invited full application: December 7, 2020. Translational Research Partnership Award Pre-application: August 12, 2020. Invited full application: December 7, 2020. Med-RA deadline to receive draft pre-application documents: August 3. Lupus Research Program Idea Award Pre-application (letter of intent): August 25, 2020. Application: September 23, 2020. Impact Award Pre-application (letter of intent): August 25, 2020. Application: September 23, 2020. Transformative Vision Award Pre-application (letter of intent): August 25, 2020. Application: September 23, 2020. Med-RA deadline to receive draft pre-application documents: August 12. NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional) The NIDA Avant-Garde Award Program for HIV/AIDS Research supports exceptionally creative scientists, who propose high-impact research that will open new areas of HIV/AIDS research in the context of Substance Use Disorders (SUD) and/or lead to new avenues for prevention and treatment of HIV/AIDS in people who use drugs (PWUD). The term ?avant-garde? refers to highly innovative ideas and/or approaches that have the potential to be transformative. Applications responding to this FOA must propose research that is substantially different from what is currently being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvHoJNHrRk$ . The NIDA Avant-Garde award supports innovative basic, clinical and translational research that may lead to improved therapies or preventive interventions for HIV/AIDS for PWUD; creative, new strategies to prevent HIV transmission in high-risk drug using populations; novel approaches to improve HIV and HIV-related comorbid disease outcomes; and creative approaches to eradicating HIV and improving the lives of PWUD living with HIV in general. Due August 13, 2020; August 13, 2021; and August 15, 2022. Med-RA deadline to receive draft documents for August 13, 2020 due date: August 3. Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional) The Avenir Award Program for research on Substance Use Disorders (SUD) and HIV/AIDS looks towards the future by supporting early stage investigators (ESI) proposing highly innovative studies that address NIH HIV/AIDS Research Priorities https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html__;!!PhOWcWs!g5Af6a_-UqX8D7GUdd3Z9NQDc0DG_LA-SdGtzjzvmWBYpzE6BiVHU1cmVRJnwy5R28Ia4_8EPqvHoJNHrRk$ . The Avenir Award Program will support creative individuals who wish to pursue innovative research at the nexus of SUD and HIV/AIDS. The purpose of this program is to support broad spectrum of approaches spanning both basic and clinical research that have the potential to benefit substance using populations with or at risk for HIV/AIDS by reducing HIV incidence, optimizing therapies for HIV and SUD, reducing the impact of comorbid conditions, and ultimately, eradicating HIV. Applications responding to this FOA must clearly describe the intersection of substance use disorders with HIV/AIDS. Due August 13, 2020; August 13, 2021; and August 15, 2022. Med-RA deadline to receive draft documents for August 13, 2020 due date: August 3. Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) This award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow?s leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies. The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow?s leaders in the field of genetics or epigenetics of substance use disorders. October 19, 2020; October 19, 2021; and October 19, 2022. Med-RA deadline to receive draft documents for October 19, 2020 due date: October 6. Advancing HIV/AIDS Research through Computational Neuroscience FOA (R01 ? Clinical Trial Optional) This funding opportunity announcement invites computational HIV/AIDS research as it relates to NIDA?s mission through collaborative research between investigators with experimental expertise related to HIV/AIDS and those with computational proficiency, including scientists from statistics, physics, mathematics, engineering, and computer science. An R01 research project should build on well-established computational strategies (theory, models, and methods) to investigate HIV-related neurocognitive deficits and neuropathogenesis in the context of substance use or substance use disorder. Due November 6, 2020. Med-RA deadline to receive draft documents: October 26. Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention and Cross-Cutting Foundational Research (P01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) solicits grant applications that propose research that can be translated into interventions in order to reduce infection and transmission of HIV in patients with alcohol use disorders. Due November 17, 2020. Med-RA deadline to receive draft documents: November 3. NSF: Ecology and Evolution of Infectious Diseases (EEID) The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to developing countries are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, epidemiologists, evolutionary biologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases. Due November 18, 2020. Med-RA deadline to receive draft documents: November 4. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Mon Jun 15 10:01:02 2020 From: Research at med.fsu.edu (Med Research) Date: Mon, 15 Jun 2020 14:01:02 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A16CE3E9@FSUCOM128.med.ad.fsu.edu> COVID-19 Forecasts Notice of Intent to Publish a Funding Opportunity Announcement for Digital healthcare interventions to address the secondary health effects related to social, behavioral, and economic impact of COVID-19 (R01 - Clinical Trial Optional) Estimated FOA publication date: June 20. Estimated application deadline: July 20. The National Institute of Mental Health (NIMH) with other ICs are issuing this Notice of Intent to Publish a Funding Opportunity Announcement to promote new initiatives that will solicit applications to support research to determine the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), wearable devices] to address secondary health effects of the social, behavioral, and economic changes following the COVID-19 pandemic, particularly among populations who experience health disparities and vulnerable populations. This FOA will utilize the R01 activity code and academic researchers will be required to partner with digital health developers and/or existing well-established digital health delivery platforms to prepare and submit applications. This notice is provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive applications. This Notice encourages investigators to acquire and leverage partnerships with digital health developers and/or existing well-established digital health delivery platforms, to consider applying for research support that follows a deployment-focused model of services design and testing. Research areas supported under this program include: reach, access, engagement, and effectiveness to screen and treat health conditions at scale not possible through traditional healthcare settings, including for areas and populations where healthcare access may be limited or not utilized. Proposed research should reflect the highest impact, with rigorous methods including sufficient power, and consideration of urgent public health needs in the context of populations eligible for consideration under this effort. This FOA will require focus on health disparate and vulnerable populations. Notice of Intent to Publish a Funding Opportunity Announcement for Community Interventions to Address the Consequences of the COVID-19 Pandemic for Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional) Estimated FOA publication date: June 22. Estimated application deadline: July 22. The National Institute of Minority Health and Health Disparities (NIMHD), with the other participating NIH Institutes, Centers, and Offices(ICOs), intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit research to evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, sociocultural, behavioral, and socioeconomic consequences of the pandemic on the health of these groups. This FOA will utilize the R01 activity code. Researchers will be encouraged to partner with community organizations, health service providers, public health agencies, policymakers, and other stakeholders to prepare and submit applications. This Notice encourages investigators to acquire and leverage partnerships with key stakeholders to test community interventions to ameliorate the impact of psychosocial, sociocultural, behavioral, and socioeconomic consequences of COVID-19 on the health of populations known to experience health disparities and other vulnerable populations. Projects may evaluate existing or ongoing community-based programs or policies (i.e., natural experiments) or prospectively test new or adapted interventions. Projects that do not solely target individuals but also address the upstream determinants that influence individual functioning and health outcomes will be strongly encouraged. Proposed research should reflect the highest impact, with rigorous methods including sufficient power, and consideration of urgent public health needs in the context of populations eligible for consideration under this effort. Projects must focus on U.S. NIH-designated health disparity populations and/or COVID-19 vulnerable populations. NIH-designated health disparity populations include racial and ethnic minorities, socioeconomically disadvantaged populations, underserved rural populations, and sexual and gender minorities. COVID-19 vulnerable populations include residents of chronic care and assisted living facilities; community-dwelling older adults; individuals with cognitive impairment or dementia; homeless populations; incarcerated populations and those involved with the criminal justice system (e.g., participants of re-entry programs); adults with medical comorbidities; pregnant women; children and adolescents; individuals with substance use disorders or severe mental illness, those living in congregate housing (e.g., shelters, residential treatment or assisted living); persons who are deaf or with disabilities including visual, hearing, communication, or mobility impairment; detainees in immigration centers; migrant communities; individuals living on tribal lands or reservations; and communities that are exposed to high rates of air pollution or other toxic exposures. Vulnerable groups also include those on the frontlines of healthcare during the COVID-19 pandemic, and those working in essential business operations (e.g., grocery and pharmacy workers, transportation, hospital and community janitorial/sanitation workers, waste collectors, postal and other delivery service workers, warehouse personnel, etc.). Alzheimer?s Drug Discovery Foundation: Neuroimaging and CSF Biomarker Development Program Specifically, this RFP focuses on: * developing novel PET ligands for clinical use * supporting novel CSF biomarkers * validating established MRI approaches in larger cohorts Novel biomarkers of neuroinflammation and synaptic integrity are considered high priority. Other target areas of interest include: * Neuronal loss * Vascular injury and blood-brain barrier integrity * Mitochondria and metabolic function * Protein misfolding/proteostasis * Oxidative stress * White matter changes * Other novel targets supported by compelling biological rationale and connection to disease The ADDF has limited interest in CSF measures of amyloid and tau. Average Award: Up to $600,000 based on stage and scope of research. No IDC. Average Duration One year with potential for follow-on funding. Multi-year proposals can be considered. Letter of intent due July 10, 2020 and October 9, 2020. Med-RA deadline to receive draft documents for July 10 letter of intent deadline: June 29. American Association for Cancer Research: Science of the Patient The Science the Patient Grants Program represents a joint effort to stimulate novel research aimed at understanding the influence of the biology of the host (i.e., patient) on the genesis, development, treatment, and survivorship of cancer. Successful projects should emphasize the interplay of host physiological systems with the tumor and/or tumor microenvironment. Harnessing the powerful approach of examining cancer not as an isolated phenomenon but as a systemic disease that affects and is affected by both the normal and pathological functions of the patient?s body, these grants are expected to yield important advancements in our understanding of cancer development, progression, and treatment. Individuals with innovative ideas that have the potential to affect future clinical practice are particularly encouraged to apply. 3 year projects; $750,000; 10% IDC. Letter of intent due July 13, 2020. Med-RA deadline to receive draft documents: June 29. Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional) This Funding Opportunity Announcement (FOA) is associated with the COVID-19 Supplement funded through the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) which directs the National Cancer Institute of the NIH ?to develop, validate, improve, and implement serological testing and associated technologies.? The purpose of the FOA is to establish Serological Sciences Research Projects with the goals of: identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection; understanding the mechanisms driving the serological, humoral and cellular immune responses; determining host, genetic, and environmental modifiers of the immune response; and determining the serological correlates of disease pathogenesis and protection against future infection; defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing. These U01 Research Projects will be part of a Serological Sciences Network (SeroNet). Other components of the Network will include Serological Sciences Centers of Excellence (U54), the FNLCR Serology Laboratory, Serological Capacity Building Centers (CBC), and a Serological Sciences Network Coordinating Center (SSNCC), which will be managed through the Frederick National Lab for Cancer Research (FNLCR), a Federally Funded Research and Development Center. It may also include SBIR grants and other grants and contracts related to serology associated with SARS-CoV-2. All components are expected to collaborate across the entire Network, sharing data, results, and reagents. Due July 22, 2020. Med-RA deadline to receive draft documents: July 9. Interventions among People Living with HIV (R21 / R01 Clinical Trial Optional) R21 R01 The purpose of these Funding Opportunity Announcements (FOAs) is to provide support for research designed to optimize smoking cessation treatment among people living with HIV (PLWH) in the United States. Responsive applications must propose research that will be conducted with PLWH and will inform efforts to reduce the incidence of tobacco-related morbidity and mortality among PLWH. Research may address the behavioral and sociocultural factors and conditions that are associated with cigarette smoking among PLWH and may also address smoking-related health disparities among PLWH, considering the heterogeneity across the various subgroups of PLWH. These FOAs aim to support research to systematically test existing evidence-based smoking cessation interventions (e.g., combination of behavioral and pharmacological) and/or to develop and test adaptations of evidence-based smoking cessation interventions among PLWH. The principal focus of this initiative is on cigarette smoking cessation; however, studies that address dual/poly tobacco product use as part of a cigarette smoking cessation intervention are acceptable. Proposed projects must include prospective, comparative evaluation(s) of the intervention(s) in terms of the rates of cigarette smoking cessation, including sustained abstinence, among current cigarette smokers. Due September 4, 2020. Med-RA deadline to receive draft documents: August 24. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Mon Jun 29 08:37:49 2020 From: Research at med.fsu.edu (Med Research) Date: Mon, 29 Jun 2020 12:37:49 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A16D255E@FSUCOM128.med.ad.fsu.edu> Congressionally Directed Medical Research Programs Chronic Pain Management Research Program Investigator Initiated Research Award Pre-application (preproposal): August 7, 2020. Application: November 6, 2020. Translational Research Award Pre-application (preproposal): August 7, 2020. Application: November 6, 2020. Med-RA deadline to receive draft documents for August 7 pre-application due date: July 27. National Organization for Research Disorders: Rare Disease Research Grant Program NORD?s Rare Disease Research Grant Program is accepting proposals for the study of the following rare diseases. Appendix Cancer and Pseudomyxoma Peritonei (PMP) ? Two 2-year grants of up to $50,000 each. Neuroendocrine Cell Hyperplasia of Infancy (NEHI) ? One grant of up to $50,000. Initial application due August 25, 2020. Med-RA deadline to receive draft documents: August 12. Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional) This Funding Opportunity Announcement (FOA) encourages applications to implement and evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, behavioral, and socioeconomic consequences of the pandemic on the health of these groups. Due August 28, 2020 and December 1, 2020. Med-RA deadline to receive draft documents for August 28 due date: August 17. DARPA: Harnessing Enzymatic Activity for Lifesaving Remedies (HEALR) The goal of the HEALR program is to develop new medical countermeasures against bacterial pathogens and their toxins by leveraging host degradation and deactivation pathways. Due September 17, 2020. Med-RA deadline to receive draft documents: August 14. This application requires extensive administrative effort, so the budget must be finalized no later than August 14 in order accommodate DARPA and RAMP system requirements. If you are interested in this opportunity please notify Med-RA (research at med.fsu.edu ) and Terra Bradley (terra.bradley at med.fsu.edu) as soon as possible. Interventions to Prevent Electronic Nicotine Delivery Systems (ENDS) Use Among Adolescents (R01 ? Clinical Trial Optional) The purpose of this funding opportunity announcement is to support (1) research to test the efficacy or effectiveness of interventions to prevent initiation and/or escalation of ENDS (electronic nicotine delivery system) use among adolescents; and(2 )research on the impact of tobacco control policies, including ENDS-specific policies, on adolescent ENDS use behavior. Of priority is research that is theoretically based and identifies specific risk and protective factors to target through prevention intervention, or research on policies that can impact adolescent ENDS use. Particularly, for prevention intervention research (e.g., school, community, and clinic-based), collaboration with stakeholders and likely program adopters is required to ensure feasibility for implementation, scalability, dissemination and sustainability. For this funding announcement, individuals as young as 12 and as old as 18 encompass the core target age range. Justification for the specific age or age range of the target population is required, including studies that propose targeting youth outside the core age range. Due October 19, 2020. Med-RA deadline to receive draft documents: October 6. 3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed) Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) as a part of its Beau Biden Cancer Moonshot Initiative invites submission of applications requesting support for projects that will accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) as Recommendation I: Generation of Human Tumor Atlases. The overarching goal of this FOA is to accelerate research efforts conducted and led by the Human Tumor Atlas Network (HTAN, humantumoratlas.org) via the implementation of three-dimensional (3D) imaging technologies that will allow for a comprehensive view of the dynamic multidimensional ecosystems that define tumors in humans. Each project will lead to the multiplexed 3D characterization of at least one cancer transition investigated by the HTAN (pre-malignant to malignant, primary to metastatic, therapy responsive to resistant). The data and analytical tools generated through this FOA will be made available for use by the research and clinical communities through the activities of the HTAN Data Coordinating Center. Due November 9, 2020. Med-RA deadline to receive draft documents: October 27. NSF: Dynamics of Integrated Socio-Environmental Systems (DISES) The DISES Program supports research projects that advance basic scientific understanding of integrated socio-environmental systems and the complex interactions (dynamics, processes, and feedbacks) within and among the environmental (biological, physical and chemical) and human ("socio") (economic, social, political, or behavioral) components of such a system. The program seeks proposals that emphasize the truly integrated nature of a socio-environmental system versus two discrete systems (a natural one and a human one) that are coupled. DISES projects must explore a connected and integrated socio-environmental system that includes explicit analysis of the processes and dynamics between the environmental and human components of the system. Due November 16, 2020. Med-RA deadline to receive draft documents: November 5. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: